<DOC>
	<DOCNO>NCT02072044</DOCNO>
	<brief_summary>Anlotibib ( AL3818 ) kind innovative medicine approve State Food Drug Administration（SFDA:2011L00661） research Jiangsu Chia-tai Tianqing Pharmaceutical Co. , Ltd. Anlotinib kinase inhibitor receptor tyrosine multi-targets , especially VEGFR2、VEGFR3、PDGFRβ c-Kit . It obvious resistance new angiogenesis . The trial explore efficacy safety profile Anlotinib patient advance Renal Cell Carcinoma ( RCC ) fail TKIs therapy .</brief_summary>
	<brief_title>Phase II Study Anlotinib Patients With Advanced Renal Cell Carcinoma（RCC）That Have Failed Or Are Intolerant To TKIs Therapy</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<criteria>1.Patients histologically confirm advanced renal cell carcinoma include clear cell component available surgery 2.Previously Failed Or Are Intolerant To TKIs Therapy ( sunitinib , Sorafenib ) 3.With measurable disease ( use RECIST1.1 ) 4.1875years , ECOG PS:01 , Life expectancy 3 month 5.Last TKIs Therapy≥4 week 6.Main organ function normal 7.Signed date informed consent 1.patients many influence factor toward oral medication 2.Known brain metastasis 3.patients severe fail controlled disease , include : suboptimal blood pressure control ; suffer myocardial ischemia grade I myocardial infarction , arrhythmias Class I heart failure ; activity failure control severe infection ; liver disease cirrhosis , decompensated liver disease , chronic active hepatitis ; poorly control diabetes ( FBG ) &gt; 10mmol/L ) ; urine protein≥++ , etc . 4.patients fail heal wound fracture Longterm 5.patients occur venous thromboembolic event within 6 month 6.patients HIVpositive organ transplantation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Renal Cell Carcinoma（RCC）</keyword>
	<keyword>Anlotinib</keyword>
</DOC>